Houston software development firm Axon is planning its Texas expansion thanks to its recent acquisition. Photo courtesy of Axon

For Owen D. Goode, Houstonians have a propensity for never being satisfied — and that's been extremely advantageous for his business.

“There’s this feeling in Houston of not being finished yet that I love,” says Goode. “Nobody is every fully satisfied in the best possible way. Nobody is sitting back and saying, ‘This is the best we could have done.’”

Goode, formerly the CEO of Axon, comes from an aviation background that includes operating as both pilot and mechanic. He now uses those skillsets in a very different world—helping to lead a company that focuses on system transformation. Axon, which was founded in 2017 was a boutique software firm focused on cloud engineering and data engineering.

This January, a larger company, Zaelot, led by CEO Jeff Lombard, acquired Axon. Zaelot is a global, software firm with a presence in 14 countries, mostly focused in the United States, Uruguay, and Iceland.

“Together we have a strong suite of offerings across a wide variety of domains including full-stack development, cloud/data engineering, design, staff augmentation, project management, and software architecture. We also have experience in multiple domains, including health care, aviation, defense, finance, and startups,” says Goode.

To the layman, this sounds impressive—and complicated—but what does Zaelot, actually do? Asked to explain at a kindergarten level, Goode says, “We take old code and make it less bad.”

With the motto, “Solve Today, Build Tomorrow,” Goode has worked with companies such as a major international airline to clean up its back end. Using a real estate analogy, Goode says that he and his team transform brownfield development environments (“a half-finished building that’s messy and there’s sewage everywhere”) into greenfield ones. It’s essentially a fresh start for sites that have become muddled over years of neglect.

“Health care is notoriously bad for that,” Goode says, though he is unable to disclose specific past or present clients.

Thanks to the merger with Zaelot, Goode and his team are now poised for rapid growth. Becoming part of a 100-person multinational company has now unlocked capital that Axon had never seen before. Goode promises rapid expansion in Texas, beginning in Houston in the next six months to a year. The executive—now Zaelot’s executive vice president—is already a well-known face on the Houston scene, where he regularly attends Cup of Joey and other Houston community events, such as CodeLaunch.

That growth includes gaining office space and expanding his staff in Space City.

“Zaelot's claim to fame is an extreme focus on employee satisfaction, with a 94 percent retention rate,” he says.

It’s his goal to keep those numbers up by serving the people who work for and with the company and treating them as human beings with families, not interchangeable parts. Next on the horizon, Goode says he and his team will be hiring sales and technical account management positions.

Though Zaelot’s staff is distributed around the world, Goode says Houston will always be home base for him. “It’s a literal launchpad that we’re continuing to grow off of,” he says. “I’m a big believer in Texas in general. And I’m just excited to see what happens.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”